An Open-label Extension Trial to Investigate the Safety and Tolerability of Long-term Treatment With Transdermal Rotigotine in Subjects With Idiopathic Restless Legs Syndrome.

Trial Profile

An Open-label Extension Trial to Investigate the Safety and Tolerability of Long-term Treatment With Transdermal Rotigotine in Subjects With Idiopathic Restless Legs Syndrome.

Completed
Phase of Trial: Phase III

Latest Information Update: 30 Oct 2014

At a glance

  • Drugs Rotigotine (Primary)
  • Indications Restless legs syndrome
  • Focus Adverse reactions; Registrational
  • Sponsors Schwarz Pharma AG; UCB
  • Most Recent Events

    • 18 Jun 2010 12-month results were presented at the 14th International Congress of Parkinson's Disease and Movement Disorders, according to a UCB media release.
    • 15 Sep 2009 Company UCB added as trial sponsor and affiliate as reported by ClinicalTrials.gov.
    • 18 Dec 2007 Status change from in progress to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top